HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nitroparacetamol (NCX-701) and pain: first in a series of novel analgesics.

Abstract
The combination of numerous classic drugs with nitric oxide donors has led to the development of new compounds with promising therapeutic activities in a great variety of situations, including cardiovascular and respiratory systems, ocular pressure, inflammation, and pain. One of the first compounds developed was NCX-701 or nitroparacetamol, resulting from the combination of paracetamol, a classic and popular analgesic used in a great number of over-the-counter medications because of its antipyretic and analgesic properties, and a nitrooxybutyroyl moiety, which releases nitric oxide at a low but steady level. Although paracetamol is devoid of most of the gastrointestinal toxicity associated with aspirin-like drugs, this type of compounds was first designed to take advantage of the cytoprotective properties of nitric oxide when released at low concentrations. However, the combination of these molecules also resulted in an unexpected enhancement of the analgesic activity of paracetamol. In fact, NCX-701 has been shown to be effective in acute nociception as well as in neuropathic pain, situations in which paracetamol and other COX inhibitors are devoid of any effect. In addition, NCX-701 is more potent and, in some circumstances, more effective than its parent compound in different models of inflammatory pain. Furthermore, whereas paracetamol lacks any effective antiinflammatory action, NCX-701 might reduce inflammation. All these results taken together imply that the mechanism of action of NCX-701 is different from that of paracetamol, although it is not yet established for either molecule. NCX-701 appears to be a promising compound in the treatment of different types of pain, with a likely better profile of side effects than its parent molecule, paracetamol. Although recent clinical trials provided data consistent with the preclinical profile of NCX-701, further studies are needed to support its clinical use.
AuthorsE Alfonso Romero-Sandoval, M Mar Curros-Criado, Gema Gaitan, Carlos Molina, Juan F Herrero
JournalCNS drug reviews (CNS Drug Rev) Vol. 13 Issue 3 Pg. 279-95 ( 2007) ISSN: 1080-563X [Print] United States
PMID17894645 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Chemical References
  • Analgesics
  • Nitrates
  • Acetaminophen
  • 4-(nitroxy)butanoic acid 4-acetylaminophenyl ester
Topics
  • Acetaminophen (analogs & derivatives, pharmacology, therapeutic use)
  • Analgesics (pharmacology, therapeutic use)
  • Animals
  • Humans
  • Nitrates (pharmacology, therapeutic use)
  • Pain (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: